Enjoy complimentary customisation on priority with our Enterprise License!
The oral cancer therapeutics market size is estimated to grow by USD 1.61 billion at a CAGR of 10.03% between 2023 and 2028. Oral cancer, a type of cancer that develops in the mouth or throat, is a significant global health concern. Its incidence and prevalence have been on the rise, with an estimated 350,000 new cases diagnosed each year. Risk factors for oral cancer include tobacco use, heavy alcohol consumption, and the human papillomavirus (HPV) infection. With growing awareness about oral cancer and its risk factors, there is a renewed focus on prevention and early detection. Regular oral examinations, avoiding risky behaviors, and maintaining a healthy lifestyle are essential steps in reducing the risk of developing oral cancer. Early detection through regular screenings can significantly improve treatment outcomes and save lives. The importance of oral health cannot be overstated, and it is crucial to prioritize regular check-ups and oral cancer screenings to safeguard your overall health.
For More Highlights About this Report, Request Free Sample
The market is witnessing significant growth due to the rising prevalence of oral cancer, driven by tobacco consumption, alcohol consumption, and the human papillomavirus (HPV). Oral cancer treatment includes surgery, radiation therapy, chemotherapy, targeted therapy, and minimally invasive surgeries. Surgery remains the primary treatment method, while radiation therapy and chemotherapy are used for advanced stages. Targeted therapy and immunotherapy are emerging treatment options. Diagnostic techniques, imaging technologies, and biomarker testing play a crucial role in early detection and treatment. Molecular diagnostics and geriatric population are gaining importance in the market. Research institutions, healthcare organizations, the Oral Cancer Foundation, and dental technology developments are also contributing to market growth. However, side effects such as hair loss, mouth sores, and loss of appetite limit the patient's quality of life and hinder market growth. The elderly population, with a higher risk of oral cancer, is a significant market segment. Root caries and pearl are also factors influencing the market. The market is expected to grow, driven by changing lifestyles and advancements in technology. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
The increasing incidence and prevalence of oral cancer is notably driving market growth. The global market is experiencing significant growth due to the rising incidence and prevalence of oral cancers, particularly squamous cell carcinoma and verrucous carcinoma. According to the Oral Cancer Foundation, approximately 54,000 Americans are expected to be diagnosed with oral cavity and pharynx cancer in the US this year. Oral cancers are more common in men than women, and the lack of dexterity in elderly patients and those with conditions like Type 2 diabetes can hinder early diagnosis.
Furthermore, clinical trials for new therapeutics are ongoing to address the unmet need for effective treatments, as current options such as chemotherapy and targeted therapy have not significantly reduced mortality rates. Hospitals and clinics, dentists, and ENT specialists are key players in the market, providing diagnosis and treatment services to patients. The increasing burden of oral cancer is expected to attract pharmaceutical companies to invest in the development of novel therapies, thereby driving market growth. Thus, such factors are driving the growth of the market during the forecast period.
Increasing R&D of new drugs is the key trend in the market. The market is witnessing significant growth due to the rising incidence of oral cancer and the need for advanced treatment options. Oral cancer encompasses various types, including squamous cell carcinoma and verrucous carcinoma. Patients with oral cancer, particularly those with dentures or lack of dexterity, often face challenges in accessing appropriate treatment. Therefore, there is a growing focus on the development of novel therapeutics and combination therapies to address this unmet need. For instance, Gliknik Inc. is advancing the clinical trial stage of biropepimut-S (GL-0817), a peptide immunomodulator, for the treatment of squamous cell carcinoma of the oral cavity.
This targeted therapy is designed to prevent the recurrence of high-risk squamous cell carcinoma by targeting important epitopes within the cancer protein MAGE-A3. The clinical trial for biropepimut-S (GL-0817) is ongoing in seven countries, involving hospitals and clinics, and is being conducted in collaboration with dentists and ENT specialists. Additionally, other oral conditions, such as oral leukoplakia and erythroplakia, are also being explored as potential indications for this therapy. Type 2 diabetes, a known risk factor for oral cancer, is also being considered as a potential patient population for biropepimut-S (GL-0817). Thus, such trends will shape the market's growth during the forecast period.
Side effects of chemotherapeutics is the major challenge that affects the growth of the market. Oral cancer, which includes squamous cell carcinoma and verrucous carcinoma, can be debilitating for patients, particularly those with lack of dexterity due to advanced age or dental issues such as dentures. Clinical trials continue to explore new treatment options, including chemotherapeutics, to improve survival rates and reduce side effects. Common chemotherapeutics used in oral cancer treatment include Carboplatin, 5-fluorouracil, paclitaxel (TAXOL), docetaxel (TAXOTERE), and hydroxyurea.
However, these treatments come with side effects, such as nausea and vomiting, which can significantly impact patients' quality of life. Delayed acute chemotherapy-induced nausea and vomiting can be challenging to manage, especially in hospitals and clinics, where patients may require constant monitoring. Furthermore, gastrointestinal side effects can lead to local ulceration, pain, malabsorption, anemia, and fatigue. Patients with conditions like Type 2 diabetes, oral leukoplakia, or erythroplakia may be more susceptible to these side effects. Dentists and ENT specialists play a crucial role in managing oral cancer patients' overall health and ensuring they receive appropriate care during chemotherapy treatment. Hence, the above factors will impede the growth of the market during the forecast period
The market forecasting report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Amneal Pharmaceuticals Inc. - The company develops Oral Cancer Therapeutic products.
The market research and growth report also includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
The market share growth by the Targeted therapy segment will be significant during the forecast period. Oral cancer treatment encompasses various modalities including surgery, radiation therapy, chemotherapy, and targeted therapy. Surgery remains a primary treatment option for early-stage oral cancer, while advanced stages may require a combination of modalities. Risk factors such as tobacco consumption, alcohol consumption, and human papillomavirus infection contribute significantly to the incidence of oral cancer.
Get a glance at the market share of various regions Download the PDF Sample
The Targeted therapy segment showed a gradual increase in the market share of USD 1.28 billion in 2018. Changing lifestyles and an aging population further increase the prevalence of this disease. Diagnostic techniques, such as biopsies and imaging tests, play a crucial role in early detection and accurate diagnosis. Advanced technologies, including molecular diagnostics and imaging technologies, facilitate early identification and personalized treatment plans. The geriatric population and healthcare organizations are focusing on patient-centric approaches, including telemedicine and remote monitoring, to improve access to oral cancer care. Dental technology developments, such as minimally invasive surgeries and root caries prevention, aim to reduce side effects, including hair loss, mouth sores, loss of appetite, nausea, and vomiting. The global geriatric population and the increasing prevalence of oral cancer necessitate a global footprint for oral cancer treatments, with research institutions at the forefront of developing new and effective therapies. The side effects of traditional oral cancer treatments, such as surgery, radiation therapy, and chemotherapy, have led to the exploration of new treatment modalities and the integration of technology to enhance patient care and improve outcomes. The global oral cancer market is expected to grow significantly due to the increasing burden of disease, aging population, and advancements in technology and treatment modalities.
For more insights on the market share of various regions Download PDF Sample now!
North America is estimated to contribute 52% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
Oral cancer, a formidable health concern, necessitates effective treatment strategies. Traditional methods include surgery, radiation therapy, and chemotherapy. Minimally invasive surgeries are increasingly popular due to reduced recovery time and fewer side effects. Tobacco consumption and alcohol intake are significant risk factors, while human papillomavirus (HPV) infection is on the rise due to changing lifestyles. Diagnostic techniques, such as biopsies and imaging tests, aid in early detection. Imaging technologies and molecular diagnostics, including Pearl, are advanced tools in oral cancer detection. The geriatric population is disproportionately affected, necessitating patient-centric approaches, telemedicine, and remote monitoring. Research institutions and healthcare organizations collaborate to develop new oral cancer treatments, such as targeted therapy. Dental technology advancements offer promising solutions for root caries prevention. Side effects like hair loss, mouth sores, loss of appetite, nausea, and vomiting necessitate improved healthcare infrastructure. The global geriatric population's oral cancer treatments require a global footprint, with a focus on smoking cessation, HPV vaccination, and early detection.
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Billion " for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
Head and Neck Cancer Treatment Market: Head and Neck Cancer Treatment Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, China, Germany, UK, Japan - Size and Forecast
Cancer Biologics Market: Cancer Biologics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, China - Size and Forecast
Breast Cancer Therapeutics Market: Breast Cancer Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast
Oral cancer is a significant health concern worldwide, and the demand for effective treatments is on the rise. Oral cancer treatment includes various modalities such as surgery, radiation therapy, chemotherapy, targeted therapy, and minimally invasive surgeries. Tobacco consumption, alcohol consumption, and human papillomavirus infection are leading risk factors for oral cancer. Changing lifestyles and the elderly population are also contributing to the increasing incidence of oral cancer. Diagnostic techniques, imaging technologies, and biomarker testing play a crucial role in early detection and accurate diagnosis of oral cancer. Molecular diagnostics and advanced technologies, such as Pearl, are revolutionizing oral cancer treatment. Side effects of oral cancer treatments, including hair loss, mouth sores, loss of appetite, nausea, and vomiting, are significant concerns for patients.
Furthermore, healthcare organizations and research institutions are focusing on patient-centric approaches, telemedicine, and remote monitoring to improve the patient experience. Dental technology developments, such as minimally invasive surgeries and biopsies, are also gaining popularity. The global geriatric population and the increasing global footprint of oral cancer are driving the growth of the market. Oral Cancer Foundation is one of the leading organizations dedicated to raising awareness and providing support for oral cancer patients. The market is expected to grow significantly due to the increasing incidence of oral cancer and the availability of new treatments and technologies. However, healthcare infrastructure and dental caries remain significant challenges in the market.
Market Scope |
|
Report Coverage |
Details |
Page number |
143 |
Base year |
2023 |
Historic period |
2018 - 2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.03% |
Market Growth 2024-2028 |
USD 1.61 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
8.88 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 52% |
Key countries |
US, Canada, Germany, India, and UK |
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
Key companies profiled |
Amneal Pharmaceuticals Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Cipla Inc., Eli Lilly and Co., Endo International Plc, F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Intas Pharmaceuticals Ltd., Lupin Ltd., Merck and Co. Inc., Pfizer Inc., Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for market forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Opportunity/Restraints
10 Competitive Landscape
11 Competitive Analysis
12 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.